After speaking with Jen Goldsack, co-founder of the Digital Medicine Society, manager of strategic partnerships at monARC Bionetworks, and formerly project lead at the Clinical Trials Transformation Institute, Piper Jaffray analyst Sean Wieland believes the 21st Century Cures Act is driving demand for innovative solutions to improve efficiencies in clinical trials, specifically in the areas of real world evidence and synthetic control arms. This should amount to “positive tailwinds” for Medidata Solutions (MDSO) and Iqvia (IQV), Wieland tells investors in a research note.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.